<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515762</url>
  </required_header>
  <id_info>
    <org_study_id>ALOPER-2</org_study_id>
    <nct_id>NCT00515762</nct_id>
  </id_info>
  <brief_title>Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling</brief_title>
  <official_title>Pilot Trial of Prevention of Persistent Alopecia Following Docetaxel by Means of Scalp Cooling (ELASTO-GEL CAPS)in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has
      been recently described. This pilot trial explores the capacity of a cooling cap (Elasto-gel)
      to prevent persistent alopecia in breast cancer patients treated with adjuvant docetaxel
      regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent alopecia following adjuvant docetaxel for breast cancer is a side-effect that has
      been recently described. Docetaxel is toxic to skin and skin annexes and can produce nail
      toxicity and persistent alopecia. Nail toxicity has been successfully prevented by means of
      hypothermic gloves and slippers (Elasto-gel, Southwest Technologies, Inc, North Kansas City,
      MO). This pilot trial explores the capacity of a cooling cap (Elasto-gel) to prevent
      persistent alopecia in breast cancer patients treated with adjuvant docetaxel regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients without persistent alopecia</measure>
    <time_frame>2nd year following docetaxel chemotherapy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Alopecia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1: scalp cooling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>scalp cooling</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>elasto-gel cap</intervention_name>
    <description>scalp cooling cap</description>
    <arm_group_label>1: scalp cooling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-75

          -  breast cancer stages II-III

          -  adjuvant or neoadjuvant chemotherapy with docetaxel regimens (TAC or anthracyclines
             followed by docetaxel 100 mg/m2 x 4)

        Exclusion Criteria:

          -  contraindications for adjuvant docetaxel and or anthracyclines
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>miguel martin, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>hospital clinico san carlos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2007</study_first_submitted>
  <study_first_submitted_qc>August 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2007</study_first_posted>
  <last_update_submitted>August 8, 2011</last_update_submitted>
  <last_update_submitted_qc>August 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Miguel Martin, MD</name_title>
    <organization>Hospital San Carlos</organization>
  </responsible_party>
  <keyword>persistent alopecia</keyword>
  <keyword>docetaxel</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

